{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-022872","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2023-05-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.344898+00:00","generated_at":"2026-06-14T20:56:21.121854+00:00","sec_items":["1.01","1.02","2.01","2.05","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"EyePoint sells YUTIQ to Alimera for $82.5M plus royalties, repays debt, cuts 35 jobs","bullets":["Sold YUTIQ rights to Alimera for $75M upfront + $7.5M guaranteed 2024 payments; low-to-mid double-digit royalties on US net sales above thresholds 2025-2028.","Repaid all $30M outstanding bank debt at closing, including prepayment and exit fees.","Executing workforce reduction of ~35 employees (sales/marketing and support); expects $1.2-1.6M pre-tax charges in Q2-Q3 2023.","Extends cash runway into 2025, beyond key EYP-1901 Phase 2 trial readouts.","Company transforms to pure-play drug developer focusing on EYP-1901 sustained delivery treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-022872","json":"https://secwatch.observer/filing/0000950170-23-022872.json","markdown":"https://secwatch.observer/filing/0000950170-23-022872.md","text":"https://secwatch.observer/filing/0000950170-23-022872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023022872/0000950170-23-022872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023022872/eypt-20230517.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T20:56:21.121854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37e2e03b31169704577b1f348ab4e5156dee0519","claim":"EyePoint, Inc. completed a disposition involving Alimera Sciences, Inc. for Upfront payment of $75 million, four quarterly guaranteed payments totaling $7.5 million during 2024, and royalties from 2025 to 2028 at a percentage of low-to- (closed 2023-05-17).","evidence_excerpt":"(the “ Company ”) entered into a product rights agreement (the “ Product Rights Agreement ”) with Alimera Sciences, Inc. (“ Alimera ”) to grant to Alimera an exclusive (even as to the Company) and sublicensable (in accordance with the terms of the Product Rights Agreement) right and license (the “ License ”) under the Company’s and its affiliates’ interest in certain of the Company’s and its affiliates’ intellectual property to develop, manufacture, sell, commercialize and otherwise exploit certain products, including YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for the treatment and prevention of uveitis in the entire world except Europe, the Middle East and Africa (the “ Licensed Territory ”).","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023022872/0000950170-23-022872-index.htm","confidence":0.95,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Alimera Sciences, Inc."},{"label":"Consideration","value":"Upfront payment of $75 million, four quarterly guaranteed payments totaling $7.5 million during 2024, and royalties from 2025 to 2028 at a percentage of low-to-"},{"label":"Closing","value":"2023-05-17"}],"fact_type":"ma_transaction"},{"claim_id":"78f134d216e9980ac52e6007e12f668c657001bd","claim":"EyePoint, Inc. entered into Product Rights Agreement with Alimera Sciences, Inc. valued at $75 million (effective 2023-05-17).","evidence_excerpt":"On May 17, 2023 (the \" Closing Date \"), EyePoint Pharmaceuticals, Inc. (the \" Company \") entered into a product rights agreement (the \" Product Rights Agreement \") with Alimera Sciences, Inc. (\" Alimera \") to grant to Alimera an exclusive (even as to the Company) and sublicensable (in accordance with the terms of the Product Rights Agreement) right and license (the \" License \") under the Company’s and its affiliates’ interest in certain of the Company’s and its affiliates’ intellectual property to develop, manufacture, sell, commercialize and otherwise exploit certain products, including YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for the treatment and prevention of uveitis in the entire world except Europe, the Middle East and Africa (the \" Licensed Territory \").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023022872/0000950170-23-022872-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Alimera Sciences, Inc."},{"label":"Value","value":"$75 million"},{"label":"Effective","value":"2023-05-17"}],"fact_type":"material_agreement"},{"claim_id":"dd525444673482481b4a039d1ae7b70eb12d6368","claim":"EyePoint, Inc. announced a restructuring with charges of approximately $1.2 million to $1.6 million in total pre-tax charges affecting sales and marketing organization and other supporting roles (approximately 35 employees).","evidence_excerpt":"of a separation agreement, which includes a general release of claims against the Company. The Company estimates that the implementation of the RIF will result in approximately $1.2 million to $1.6 million in total pre-tax charges and cash outlays for termination of employees. The Company expects the charges will be incurred primarily in the second quarter of 2023,","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023022872/0000950170-23-022872-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.2 million to $1.6 million in total pre-tax charges"},{"label":"Affected area","value":"sales and marketing organization and other supporting roles"},{"label":"Headcount","value":"approximately 35 employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}